Purchase Order HHSN271201100609P
- Not listed
- This is a firm fixed price purchase order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Illumina, Inc., a for-profit manufacturer of genomic sequencing and analysis products. The $82,507.48 contract has no set-aside designation and does not appear to be associated with a larger contracting vehicle. Under this award, Illumina will provide NIDA with various sequencing systems, reagents, consumables, and related services to support genomic research and diagnostics....
- This is a $154,713.12 firm fixed price delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Illumina, Inc., a for-profit manufacturer of genetic analysis instruments and reagents. The contract is not associated with a set-aside program. Illumina will provide sequencing systems, reagents, and maintenance services to support genomic research and analysis across a range of federal agencies, including the NIH, CDC, USDA, and VA. Illumina has previously been...
- This is a firm fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to Illumina, Inc., a manufacturer of genetic sequencing and genomic analysis instruments and consumables. The award, valued at $12,524.80, is for the delivery of Illumina sequencing systems and related products to support NIDA's research and diagnostics needs. This award is not associated with a set-aside program. Illumina has received multiple...
- This is a firm fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to Illumina, Inc. The $292,500.00 contract is for the provision of Illumina sequencing systems, reagents, and associated products and services to support genomic sequencing and analysis. Illumina is an experienced provider of sequencing and genomic analysis technologies to federal agencies, having previously supported work at the NIH, Centers for...
- The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $513,896.40 firm fixed price delivery order contract to Illumina, Inc. to provide sequencing and array-based genomic analysis solutions. Illumina, a for-profit manufacturer, will deliver a range of sequencing systems, reagents, consumables, and bioinformatics products to support the agency's research and diagnostic needs. This order is part of Illumina's existing Indefinite...
- This is a $78,707.44 firm fixed price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to Illumina, Inc. The contract does not have a set-aside designation. Illumina, a manufacturer and provider of sequencing and array-based solutions for genetic and genomic analysis, is providing various sequencing systems, reagents, consumables, and other support services to NIDA under this award. Illumina has previously received...
- This is a firm fixed price purchase order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the National Institutes of Health (NIH), to Illumina, Inc. The $252,500.00 contract is for the provision of Illumina's genetic sequencing systems, reagents, and associated services. This contract does not have a set-aside designation. Illumina is a manufacturer of genetic analysis instruments and reagents, and has previously been awarded both prime federal contracts and...
- The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a firm fixed price delivery order contract to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The $250,675.20 award, with a completion date of March 8, 2018, is for the provision of sequencing systems, reagents, consumables, and associated services to support the agency's genomics research and diagnostics efforts. Illumina has...
- This is a firm fixed price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the Department of Health and Human Services, to Illumina, Inc. The $133,624.15 contract is for the provision of Illumina's NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, accompanying reagents and consumables, sample prep kits, sequencing chips, support plans, maintenance services, and bioinformatics products. The contract has a period of performance through...
- The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a firm fixed price delivery order contract to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents. The $290,432.92 contract does not have a set-aside designation and was awarded on September 14, 2018 with a completion date of September 2, 2020. Illumina, a for-profit organization, has previously provided sequencing systems, reagents, and services to support...
The U.S. National Institute on Drug Abuse (NIDA), a civilian agency of the federal government, awarded a firm fixed-price purchase order contract to Illumina, Inc., a manufacturer of sequencing and array-based genomic analysis solutions. The $8,003.02 contract is for the delivery of a cluster kit and two sequencing kits using Illumina's proprietary technology. This award is not associated with a set-aside program. Illumina has previously secured other prime federal contracts and sub-awards from agencies like the NIH, CDC, USDA, and VA to provide a range of genomic sequencing instruments, consumables, and services in support of life science research, applied markets, and molecular diagnostics. The contract award indicates Illumina's role as a key provider of advanced sequencing capabilities to the federal government.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.0k | 8/24/11 |